Weight-loss peptides are the rare corner of this field where the top tier isn't hype: GLP-1 medications produce 15-21% average body-weight loss in trials of tens of thousands of people. The problem is everything sold underneath that tier using its halo. This pillar ranks the whole landscape by evidence - approved, investigational, and gray market - so the halo stops working on you.
Tier 1 - approved, proven, prescribable today
| Drug | Brands | Trial weight loss | Status |
|---|---|---|---|
| Tirzepatide | Zepbound, Mounjaro | ≈ 20.9% at 72 wk (SURMOUNT-1) | FDA-approved |
| Semaglutide | Wegovy, Ozempic | ≈ 14.9% at 68 wk (STEP-1) | FDA-approved |
| Liraglutide | Saxenda | ≈ 8% (older, daily injection) | FDA-approved |
These are peptides in the strict chemical sense, and they are the entire evidence-backed tier. Access runs through a prescription - in person or licensed telehealth - with insurance coverage that varies wildly and self-pay programs (LillyDirect, NovoCare) in the $350-650/month range for some doses.
Tier 2 - investigational: better numbers, no access
The next generation posts bigger trial numbers and is not purchasable: retatrutide (≈24% at 48 weeks in Phase 2, our full hub covers it) and survodutide (dual agonist, strong liver data) are in Phase 3, with plausible approvals in 2027-2028. Everything sold online under these names today is unverifiable gray market carrying explicit FDA warnings - the entire analysis lives in our retatrutide how-to-get guide.
Tier 3 - the gray market riding the halo
- AOD-9604: the honest failure - its actual Phase 2b obesity trials missed their endpoints twenty years ago. Sold anyway.
- CJC-1295 / ipamorelin: marketed for 'fat loss via growth hormone'. GH does shift body composition at pharmacological levels, but no controlled trial shows these secretagogues produce meaningful fat loss in humans.
- MOTS-c: genuinely interesting exercise-mimetic biology, entirely preclinical for weight outcomes.
- 5-Amino-1MQ: an NNMT inhibitor (not a peptide) with rodent-only fat-loss data, sold in capsules on that basis.
- The tell is always the same: rodent mechanisms cited where human endpoints should be.
What the weight actually responds to
GLP-1-class drugs work primarily by reducing appetite and slowing gastric emptying; retatrutide adds an energy-expenditure component via glucagon agonism. Two clinical realities follow. First, muscle: roughly a quarter to a third of lost mass is lean tissue unless protein intake and resistance training defend it. Second, persistence: withdrawal studies show most weight returns within a year of stopping - these are treatments, not cures, and any plan that ignores the maintenance question is half a plan.
How to choose, in practice
- Have obesity or weight-related conditions and want results now → Tier 1, with a prescriber; tirzepatide holds the best approved numbers.
- Fixated on retatrutide specifically → trial enrollment or patience; nothing else is real.
- Tempted by Tier 3 → reread the tier: you'd be paying real money for compounds that either failed trials or never reached them.
Frequently asked questions
What is the best peptide for weight loss?
Among approved options, tirzepatide (Zepbound) holds the strongest trial results - about 21% average body-weight loss. Retatrutide posted ~24% in Phase 2 but remains unapproved and inaccessible. Nothing in the gray-market tier has controlled human evidence for weight loss.
Do you need a prescription for weight-loss peptides?
For every legitimate one, yes - semaglutide, tirzepatide, and liraglutide are prescription drugs, available in person or via licensed telehealth. Anything offered without a prescription is either not a drug (supplements) or not legal (research chemicals).
How much do weight-loss peptides cost?
List prices run $1,000-1,350/month for branded GLP-1s; insurance coverage varies enormously; manufacturer self-pay programs bring some doses to $350-650/month. Compounded pricing (where still lawful) sat lower, but that channel has narrowed since the shortages ended.
Are weight-loss peptides safe?
The approved tier has the largest safety datasets in modern obesity medicine: GI side effects dominate, with class warnings (thyroid C-cell findings in rodents, pancreatitis, gallbladder). Safety of the gray-market tier is unknown by definition - no trials, no product verification.